CCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
More Information Supplier PageGSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor.
More Information Supplier PageGSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor.
More Information Supplier PageGSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PagePF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
More Information Supplier PagePF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
More Information Supplier PagePF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
More Information Supplier PagePF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
More Information Supplier PagePF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
More Information Supplier Page
